Literature DB >> 20157026

Predicting migraine responsiveness to botulinum toxin type A injections.

Christine C Kim1, Megan M Bogart, Sue Ann Wee, Rami Burstein, Kenneth A Arndt, Jeffrey S Dover.   

Abstract

BACKGROUND: Botulinum toxin type A (BTX) is used prophylactically to reduce the frequency of migraine headaches, with inconsistent responses reported in the literature. The purpose of our study was to determine whether BTX injections at doses used for upper-face cosmetic purposes, which differ from doses typically used by headache specialists, could prevent imploding and ocular but not exploding migraines. OBSERVATIONS: Study participants were recruited among patients who had received or were planning to receive BTX injections for upper-face cosmetic purposes but also reported having migraines. Among the 18 patients who completed the study, most with imploding and ocular migraines experienced a significant reduction in their headache frequency, whereas those with exploding migraines generally did not.
CONCLUSIONS: Our study supports the hypothesis that patients with imploding and ocular migraines are more responsive to BTX than those with exploding migraines. Injections of BTX at doses appropriate for cosmetic purposes may be sufficient to prevent migraine attacks.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20157026     DOI: 10.1001/archdermatol.2009.356

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  6 in total

Review 1.  Use of botulinum toxin in the neurology clinic.

Authors:  Erle C H Lim; Raymond C S Seet
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

Review 2.  Action mechanisms of Onabotulinum toxin-A: hints for selection of eligible patients.

Authors:  Carlo Lovati; Luca Giani
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

3.  Imploding and exploding migraine headaches: comparison of methods to diagnose pain directionality.

Authors:  Julia A Files; Todd J Schwedt; Anita P Mayer; Paru S David; Bert B Vargas; Yu-Hui Chang; Megan Hunt; Salma Patel; Marcia G Ko; Beverly S Tozer; Rami Burstein; David W Dodick
Journal:  Headache       Date:  2014-04-25       Impact factor: 5.887

4.  Topographic Relationship between the Supratrochlear Nerve and Corrugator Supercilii Muscle--Can This Anatomical Knowledge Improve the Response to Botulinum Toxin Injections in Chronic Migraine?

Authors:  Hyung-Jin Lee; Kwang-Seok Choi; Sung-Yoon Won; Prawit Apinuntrum; Kyung-Seok Hu; Seong-Taek Kim; Tanvaa Tansatit; Hee-Jin Kim
Journal:  Toxins (Basel)       Date:  2015-07-17       Impact factor: 4.546

5.  Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data.

Authors:  Raffaele Ornello; Simona Guerzoni; Carlo Baraldi; Luana Evangelista; Ilaria Frattale; Carmine Marini; Cindy Tiseo; Francesca Pistoia; Simona Sacco
Journal:  J Headache Pain       Date:  2020-04-25       Impact factor: 7.277

6.  Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.

Authors:  Antonio Russo; Marcello Silvestro; Fabrizio Scotto di Clemente; Francesca Trojsi; Alvino Bisecco; Simona Bonavita; Alessandro Tessitore; Gioacchino Tedeschi
Journal:  J Headache Pain       Date:  2020-06-09       Impact factor: 7.277

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.